Several in vitro studies have shown that ACEi/ARBs suppress the cell proliferative effects of angiotensin II in breast cancer by inhibiting the renin-angiotensin system and its downstream signaling proteins such as tissue factor, vascular endothelial growth factor (VEGF), and the transcription factors NF-κB and CREB [58–60]. Here, NFKB1 is linked to breast carcinoma.